Pulmonary artery sealing with ultrasonic energy in open lobectomy: A phase I clinical trial

被引:14
|
作者
Goudie, Eric [1 ]
Thiffault, Vicky [1 ]
Jouquan, Adeline [1 ]
Lafontaine, Edwin [1 ]
Ferraro, Pasquale [1 ]
Liberman, Moishe [1 ]
机构
[1] Univ Montreal, Endoscop Tracheobronchial & Oesophageal Ctr, Endoscop Tracheobronchial & Oesophageal Ctr CETOC, CHU Montreal,Dept Surg,Div Thorac Surg, Montreal, PQ, Canada
来源
关键词
pulmonary artery sealing; energy; VATS lobectomy; ultrasonic energy; THORACOSCOPIC LOBECTOMY; LUNG-CANCER; SURGERY LOBECTOMY; VASCULAR LIGATION; THORACIC-SURGERY; STAGE-I; RESECTION; DEVICES; COMPLICATIONS; THORACOTOMY;
D O I
10.1016/j.jtcvs.2016.12.049
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Pulmonary artery branch sealing in video-assisted thoracoscopic surgical lobectomy is usually achieved with vascular endostaplers. Iatrogenic pulmonary artery injury may be caused by endostaplers. We evaluated the safety of pulmonary artery sealing with an ultrasonic energy vessel-sealing device in a phase I clinical trial evaluating in vivo safety of the device during open lobectomy. Methods: Patients scheduled to undergo elective open (thoracotomy) pulmonary lobectomy were prospectively enrolled. Target sample size was 10 patients. Pulmonary artery diameter was measured intraoperatively. All branches <= 7mmwere divided with an ultrasonic energy vessel-sealing device. The remainder of the lobectomy was performed in a standard fashion. Intraoperative and postoperative bleeding were strictly recorded. Results: Eighteen patients were prospectively enrolled. Eight patients were not amenable to pulmonary artery sealing with the device. In the 10 patients included in the analysis, a total of 14 pulmonary arteries were sealed with the ultrasonic device. The mean vessel diameter was 5 mm (range, 2-7 mm). One patient underwent reoperation for bronchial artery bleeding (vessel not sealed with device). There was no intra-or postoperative bleeding related to ultrasonic pulmonary artery sealing. There was no postoperative mortality. Conclusions: Pulmonary artery sealing for vessels with diameter <= 7 mm was safely achieved with an ultrasonic energy vessel-sealing device in open lobectomy. The use of ultrasonic energy vessel-sealing devices in video-assisted thoracoscopic surgical lobectomy may have the advantage of making small, short, pulmonary artery branch sealing safer than with vascular endostaplers. Further studies are necessary before widespread application in lobectomy, including video-assisted thoracoscopic surgical lobectomy.
引用
收藏
页码:1600 / 1606
页数:7
相关论文
共 50 条
  • [31] Phase I clinical trial of olprinone in liver surgery
    Hiroaki Fuji
    Etsuro Hatano
    Kohta Iguchi
    Kenya Yamanaka
    Tomoaki Yoh
    Yoshinobu Ikeno
    Satoru Seo
    Kojiro Taura
    Kentaro Yasuchika
    Shiro Tanaka
    Hisanari Ishii
    Mariko Kobayashi
    Kazuyuki Ueno
    Shinji Uemoto
    Surgery Today, 2017, 47 : 918 - 927
  • [32] PHASE-I CLINICAL-TRIAL OF SPIROGERMANIUM
    BYRNE, PJ
    SCHEIN, PS
    MAGUIRE, P
    HOTH, D
    SMITH, F
    BROWN, J
    WOOLLEY, PV
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 351 - 351
  • [33] An evaluation of phase I cancer clinical trial designs
    Ahn, C
    STATISTICS IN MEDICINE, 1998, 17 (14) : 1537 - 1549
  • [34] PHASE-I CLINICAL-TRIAL OF MARCELLOMYCIN
    NICAISE, C
    ROZENCWEIG, M
    DODION, P
    PICCART, M
    CRESPEIGNE, N
    LENAZ, L
    KENIS, Y
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1982, 23 (MAR): : 137 - 137
  • [35] Phase I clinical trial of olprinone in liver surgery
    Fuji, Hiroaki
    Hatano, Etsuro
    Iguchi, Kohta
    Yamanaka, Kenya
    Yoh, Tomoaki
    Ikeno, Yoshinobu
    Seo, Satoru
    Taura, Kojiro
    Yasuchika, Kentaro
    Tanaka, Shiro
    Ishii, Hisanari
    Kobayashi, Mariko
    Ueno, Kazuyuki
    Uemoto, Shinji
    SURGERY TODAY, 2017, 47 (08) : 918 - 927
  • [36] Phase I clinical trial of KRN5500
    LoRusso, PM
    Foster, B
    Wozniak, A
    Flaherty, L
    Shields, A
    Zalupski, M
    Kocarek, T
    Grieshaber, CK
    Parchment, RE
    ANNALS OF ONCOLOGY, 1998, 9 : 124 - 124
  • [37] PHASE-I CLINICAL-TRIAL OF MITOZOLOMIDE
    NEWLANDS, ES
    BLACKLEDGE, G
    SLACK, JA
    GODDARD, C
    BRINDLEY, CJ
    HOLDEN, L
    STEVENS, MFG
    CANCER TREATMENT REPORTS, 1985, 69 (7-8): : 801 - 805
  • [38] CHARACTERISTICS AND ATTITUDES OF PARTICIPANTS IN A PHASE I CLINICAL TRIAL
    Singh, A.
    Apseloff, G.
    Groen, D.
    Tishler, C.
    Bartholomae, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S79 - S80
  • [39] CLINICAL TRIAL PHASE-I ANTIHYPERTENSIVE DRUGS
    KERSTING, F
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1973, 23 (11A): : 1657 - 1659
  • [40] A phase I clinical trial with OncoVEXGM-CSF
    Hu, J
    McNeish, I
    Shorrock, C
    Steiner, J
    Love, C
    Coffin, R
    Coombes, C
    MOLECULAR THERAPY, 2003, 7 (05) : S447 - S447